Target
GLP-1R
glucagon-like peptide-1 receptor
Aliases: glucagon-like peptide-1 receptor · GLP-1 receptor
Activates incretin signaling to potentiate glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite.
Mechanism summary
Activates incretin signaling to potentiate glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite.
Family: G-protein coupled receptor (GPCR), class B
Related indications
Assets targeting this mechanism
View all →| Asset | Stage | Sponsors |
|---|---|---|
| Tirzepatide | Approved | Eli Lilly |
| Semaglutide | Approved | Novo Nordisk |
| Retatrutide | Phase 3 | Eli Lilly |
| Cagrisema | Phase 3 | Novo Nordisk |
| Mazdutide | Phase 3 | Eli Lilly |
| Danuglipron | Phase 2 | Pfizer |
| Lotiglipron | Discontinued | Pfizer |
| Survodutide | Phase 2 | Boehringer Ingelheim, Zealand Pharma |
| Maritide | Phase 1/2 | Amgen |
| CT-388 | Phase 1 | Roche |
| GSBR-1290 | Phase 2 | Structure Therapeutics |
| Orforglipron | Phase 3 | Eli Lilly |
| Pemvidutide | Phase 2 | Eli Lilly |
| Efinopegdutide | Phase 2 | Eli Lilly |
| Oral semaglutide | Approved | Novo Nordisk |
Competing assets
15 assets are mapped to GLP-1R. View the asset table above to compare stages and sponsors.